Navigation Links
Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Date:11/12/2012

SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca.  Howard Robin, president and chief executive officer, will host the conference call, which will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard Time (PST).

A live audio-only Webcast of this conference call can be accessed through a link that is posted on the home page of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Thursday, December 13, 2012.

To access the conference call live by telephone, please follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international) 

Passcode: 70465377 (Nektar Therapeutics is the host)

A telephonic replay will also be available shortly following the call and can be accessed by dialing (855) 859-2056 (U.S.); or (404) 537-3406 (international) with a passcode of 70465377.  The replay will be available for approximately four weeks following the call.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

This call will replace the company's regular financial results call which was scheduled for Tuesday, November 13, 2012. 

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Thoratec Schedules First Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology:
(Date:5/25/2016)... San Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 1st, 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This ... panel discussion will be led by clinical trial experts from the pharmaceutical company Hallux, ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are ... Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients throughout ... accelerates with the implementation of MACRA, we believe that continuing to add professionals ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... The Georgia ... Award of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes ... city of Atlanta’s built environment, the preservation of its physical heritage and the balance ...
(Date:5/25/2016)... ... 2016 , ... Serenity Recovery, a holistic treatment center for ... the many supplemental program options offered at their rehabilitation facility, this time focusing ... Belt in the Shorin-ryu style of Karate that originated in Okinawa, Japan, and ...
(Date:5/25/2016)... ... ... to an article published May 5th on The Daily Mail, a survey pointed ... it found that more than a third cited unappealing breath a one of their top ... a failure to brush after meals, can typically be attributed to gum disease. Moreover, the ...
Breaking Medicine News(10 mins):